Trial Profile
Study to evaluate Circulating tumor DNA (ctDNA) as a predictive biomarker of response to Regorafenib and TAS-102 in patients with Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2018
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology